Mortality in pulmonary arterial hypertension

• Verfasst von: Höper, Marius [VerfasserIn]
• Verfasst von: Pan, Zixuan [VerfasserIn]
• Verfasst von: Eichstaedt, Christina [VerfasserIn]
• Verfasst von: Benjamin, Nicola [VerfasserIn]
• Verfasst von: Grünig, Ekkehard [VerfasserIn]
• Titel: Mortality in pulmonary arterial hypertension
• Titelzusatz: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model
• Verf.angabe: Marius M. Hoeper, Tilmann Kramer, Zixuan Pan, Christina A. Eichstaedt, Jens Spiesshoefer, Nicola Benjamin, Karen M. Olsson, Katrin Meyer, Carmine Dario Vizza, Anton Vonk-Noordegraaf, Oliver Distler, Christian Opitz, J. Simon R. Gibbs, Marion Delcroix, H. Ardeschir Ghofrani, Doerte Huscher, David Pittrow, Stephan Rosenkranz, Ekkehard Grünig
• E-Jahr: 2017
• Jahr: August 3, 2017
• Umfang: 10 S.
• Fussnoten: Gesehen am 09.05.2018
• Titel Quelle: Enthalten in: European respiratory journal
• Ort Quelle: Lausanne : ERS, 1988
• Jahr Quelle: 2017
• Band/Heft Quelle: 50(2017,2) Artikel-Nummer 1700740, 10 Seiten
• ISSN Quelle: 1399-3003
• DOI: doi:10.1183/13993003.00740-2017
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1574285394

Abstract

The 2015 European pulmonary hypertension (PH) guidelines propose a risk stratification strategy for patients with pulmonary arterial hypertension (PAH). Low-, intermediate- and high-risk strata are defined by estimated 1-year mortality risks of <5%, 5-10% and >10%, respectively. This risk assessment strategy awaits validation. We analysed data from patients with newly diagnosed PAH enrolled into COMPERA (Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension), a European-based PH registry. An abbreviated version of the risk assessment strategy proposed by the European PH guidelines was applied, using the following variables: World Health Organization functional class, 6-min walking distance, brain natriuretic peptide or its N-terminal fragment, right atrial pressure, cardiac index and mixed venous oxygen saturation. Data from 1588 patients were analysed. Mortality rates were significantly different between the three risk strata (p<0.001 for all comparisons). In the entire patient population, the observed mortality rates 1 year after diagnosis were 2.8% in the low-risk cohort (n=196), 9.9% in the intermediate-risk cohort (n=1116) and 21.2% in the high-risk cohort (n=276). In addition, the risk assessment strategy proved valid at follow-up and in major PAH subgroups. An abbreviated version of the risk assessment strategy proposed by the current European PH guidelines provides accurate mortality estimates in patients with PAH. Tweetable abstract @ERSpublications click to tweetThe risk stratification strategy proposed by the current European PH guidelines allows accurate survival prediction http://ow.ly/KsWk30c46nK